151 related articles for article (PubMed ID: 32623639)
1. Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma.
Choi S; Park S; Cho YA; Park CK; Ha SY
Pathol Oncol Res; 2020 Oct; 26(4):2587-2595. PubMed ID: 32623639
[TBL] [Abstract][Full Text] [Related]
2. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
3. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
4. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.
Lee SJ; Lee J; Sohn I; Mao M; Kai W; Park CK; Lim HY
Anticancer Res; 2013 Nov; 33(11):5179-86. PubMed ID: 24222167
[TBL] [Abstract][Full Text] [Related]
5. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CLN3 contributes to tumour progression and predicts poor prognosis in hepatocellular carcinoma.
Xu Y; Wang H; Zeng Y; Tian Y; Shen Z; Xie Z; Chen F; Sun L; Shu R; Li PP; Chen C; Yu J; Wang K; Luo H
Surg Oncol; 2019 Mar; 28():180-189. PubMed ID: 30851897
[TBL] [Abstract][Full Text] [Related]
7. Pan-TRK Immunohistochemistry and NTRK Gene Fusions in Primary Carcinomas of the Liver.
Zhang D; Liao X
Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):435-440. PubMed ID: 35587529
[TBL] [Abstract][Full Text] [Related]
8. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC.
Lin ZZ; Jeng YM; Hu FC; Pan HW; Tsao HW; Lai PL; Lee PH; Cheng AL; Hsu HC
BMC Cancer; 2010 Aug; 10():461. PubMed ID: 20799978
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
Jiang YY; Chen H; Xu BL; Wang S
Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
[No Abstract] [Full Text] [Related]
10. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis.
Ha SY; Kim JH; Yang JW; Kim J; Kim B; Park CK
Cancer Res Treat; 2016 Jul; 48(3):1065-73. PubMed ID: 26511806
[TBL] [Abstract][Full Text] [Related]
11. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
[TBL] [Abstract][Full Text] [Related]
12. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma.
Zhou ZJ; Dai Z; Zhou SL; Fu XT; Zhao YM; Shi YH; Zhou J; Fan J
Int J Cancer; 2013 Mar; 132(5):1080-9. PubMed ID: 22821376
[TBL] [Abstract][Full Text] [Related]
14. A morpho-molecular prognostic model for hepatocellular carcinoma.
Srivastava S; Wong KF; Ong CW; Huak CY; Yeoh KG; Teh M; Luk JM; Salto-Tellez M
Br J Cancer; 2012 Jul; 107(2):334-9. PubMed ID: 22713659
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma.
Chen W; Chen L; Cai Z; Liang D; Zhao B; Zeng Y; Liu X; Liu J
Tumour Biol; 2016 Jul; 37(7):9343-55. PubMed ID: 26779633
[TBL] [Abstract][Full Text] [Related]
16. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
17. Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma.
Chen S; Li K; Jiang J; Wang X; Chai Y; Zhang C; Deng Q; Shuai L; Feng K; Ma K; Zhang L
World J Surg Oncol; 2020 Jun; 18(1):127. PubMed ID: 32534581
[TBL] [Abstract][Full Text] [Related]
18. Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma.
Choi S; Lee KW; Koh HH; Park S; Yeo SY; Joh JW; Choi MS; Kim SH; Park CK; Ha SY
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3517-3534. PubMed ID: 34462784
[TBL] [Abstract][Full Text] [Related]
19. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
[TBL] [Abstract][Full Text] [Related]
20. Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.
Zheng H; Yang Y; Wang MC; Yuan SX; Tian T; Han J; Ni JS; Wang J; Xing H; Zhou WP
Surg Oncol; 2016 Sep; 25(3):171-7. PubMed ID: 27566019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
